{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T04:20:05Z","timestamp":1744086005501,"version":"3.40.3"},"reference-count":28,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"DOI":"10.2340\/actadv.v105.41972","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T13:19:29Z","timestamp":1744031969000},"page":"adv41972","source":"Crossref","is-referenced-by-count":0,"title":["Distinct Impact of Phosphodiesterade-4 (PDE4) Inhibition in Two Pre-clinical Psoriasis Models"],"prefix":"10.2340","volume":"105","author":[{"given":"S\u00f6ren","family":"Dr\u00e4ger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorge","family":"Mester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Tenor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"106669","unstructured":"Pharmindex [Internet]. [cited 2024 Aug 12]. Available from: http:\/\/www.gelbe-liste.de"},{"key":"106670","doi-asserted-by":"crossref","unstructured":"Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001; 297: 267\u2013279.","DOI":"10.1016\/S0022-3565(24)29537-9"},{"key":"106671","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0022-3565(24)29537-9","DOI":"10.1016\/S0022-3565(24)29537-9"},{"key":"106672","doi-asserted-by":"crossref","unstructured":"Man H wah, Schafer P, Wong LM, Patterson RT, Corral LG, Raymon H, et al. Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxy-(Apremilast ), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J Med Chem 2009; 52: 1522\u20131524.","DOI":"10.1021\/jm900210d"},{"key":"106673","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1021\/jm900210d","DOI":"10.1021\/jm900210d"},{"key":"106674","unstructured":"Walsh NM. Comparison of the modes of action of Apremilast and Roflumilast. Enlighten thesxes. Glasgow: University of Glasgow; 2015."},{"key":"106675","doi-asserted-by":"crossref","unstructured":"Gyldenl\u00f8ve M, Meteran H, S\u00f8rensen JA, Fage S, Yao Y, Lindhardsen J, et al. Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO). Lancet Reg Health \u2013 Eur 2023; 30: 100639.","DOI":"10.1016\/j.lanepe.2023.100639"},{"key":"106676","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100639","DOI":"10.1016\/j.lanepe.2023.100639"},{"key":"106677","doi-asserted-by":"crossref","unstructured":"Swindell WR, Johnston A, Carbajal S, Han G, Wohn C, Lu J, et al. Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis. PLoS ONE 2011; 6: e18266.","DOI":"10.1371\/journal.pone.0018266"},{"key":"106678","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1371\/journal.pone.0018266","DOI":"10.1371\/journal.pone.0018266"},{"key":"106679","doi-asserted-by":"crossref","unstructured":"Fits LVD, Mourits S, Voerman JSA, Kant M, Boon L, Laman JD, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis. J Immunol 2009; 182: 5836\u20135845.","DOI":"10.4049\/jimmunol.0802999"},{"key":"106680","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.4049\/jimmunol.0802999","DOI":"10.4049\/jimmunol.0802999"},{"key":"106681","doi-asserted-by":"crossref","unstructured":"Gauld SB, Gauvin D, Olson L, Leys L, Paulsboe S, Liu Z, et al. Mechanistic and pharmacological assessment of murine IL-23 mediated psoriasiform dermatitis: implications for drug discovery. J Dermatol Sci 2018; 92: 45\u201353.","DOI":"10.1016\/j.jdermsci.2018.08.001"},{"key":"106682","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jdermsci.2018.08.001","DOI":"10.1016\/j.jdermsci.2018.08.001"},{"key":"106683","doi-asserted-by":"crossref","unstructured":"Bieber K, Bezdek S, Gupta Y, Vorobyev A, Sezin T, Gross N, et al. Forward genetics and functional analysis highlight Itga11 as a modulator of murine psoriasiform dermatitis. J Pathol 2023; 261: 184\u2013197.","DOI":"10.1002\/path.6162"},{"key":"106684","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/path.6162","DOI":"10.1002\/path.6162"},{"key":"106685","doi-asserted-by":"crossref","unstructured":"Dr\u00e4ger S, Kalies K, Sidronio TB, Witte M, Ludwig RJ, Bieber K. Increased TREM-1 expression in inflamed skin has no functional impact on the pathogenesis of cutaneous disorders. J Dermatol Sci 2017; 88: 139\u2013155.","DOI":"10.1016\/j.jdermsci.2017.05.016"},{"key":"106686","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jdermsci.2017.05.016","DOI":"10.1016\/j.jdermsci.2017.05.016"},{"key":"106687","doi-asserted-by":"crossref","unstructured":"Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006; 203: 2577\u20132587.","DOI":"10.1084\/jem.20060244"},{"key":"106688","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1084\/jem.20060244","DOI":"10.1084\/jem.20060244"},{"key":"106689","doi-asserted-by":"crossref","unstructured":"Xu R, Feng S, Ao Z, Chen Y, Su C, Feng X, et al. Long-acting \u03b22 adrenergic receptor agonist ameliorates imiquimod-induced psoriasis-like skin lesion by regulating keratinocyte proliferation and apoptosis. Front Pharmacol 2022; 13: 865715.","DOI":"10.3389\/fphar.2022.865715"},{"key":"106690","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fphar.2022.865715","DOI":"10.3389\/fphar.2022.865715"},{"key":"106691","doi-asserted-by":"crossref","unstructured":"Uchida H, Kamata M, Shimizu T, Egawa S, Ito M, Takeshima R, et al. Apremilast downregulates interleukin-17 production and induces splenic regulatory B cells and regulatory T cells in imiquimod-induced psoriasiform dermatitis. J Dermatol Sci 2021; 104: 55\u201362.","DOI":"10.1016\/j.jdermsci.2021.08.001"},{"key":"106692","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jdermsci.2021.08.001","DOI":"10.1016\/j.jdermsci.2021.08.001"},{"key":"106693","doi-asserted-by":"crossref","unstructured":"Ernst O, Failayev H, Athamna M, He H, Tsfadia Y, Zor T. A dual and conflicting role for imiquimod in inflammation: a TLR7 agonist and a cAMP phosphodiesterase inhibitor. Biochem Pharmacol 2020; 182: 114206.","DOI":"10.1016\/j.bcp.2020.114206"},{"key":"106694","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114206","DOI":"10.1016\/j.bcp.2020.114206"},{"key":"106695","doi-asserted-by":"crossref","unstructured":"Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KHG. Interleukin-1 and IL-23 induce innate IL-17 production from \u03b3\u03b4 t cells, amplifying Th17 responses and autoimmunity. Immunity 2009; 31: 331\u2013341.","DOI":"10.1016\/j.immuni.2009.08.001"},{"key":"106696","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.immuni.2009.08.001","DOI":"10.1016\/j.immuni.2009.08.001"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/41972\/49771","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/41972\/49771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T13:19:52Z","timestamp":1744031992000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/41972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":28,"URL":"https:\/\/doi.org\/10.2340\/actadv.v105.41972","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,7]]}}}